Feline Panleukopenia Vaccine Veterinary Grade API is a purified bulk antigen fraction of feline parvovirus (FPV) intended solely for further manufacture into finished veterinary immunological products. The biologically active component is propagated on Crandell-Rees feline kidney cells (CRFK, ATCC CCL-94), clarified by depth filtration, and concentrated by tangential-flow diafiltration against a phosphate-buffered sucrose–trehalose stabiliser. Two principal downstream presentations are manufactured: the live-attenuated model FPV-API-LA-25 and the inactivated whole-virus model FPV-API-KV-25. A recombinant VP2 subunit model FPV-API-rVP2-15 is available for manufacturers requiring an adjuvant-stable antigen with no replication-competent parvovirus. The API is supplied as a sterile lyophilised powder, frozen liquid, or refrigerated suspension, depending on the model and the intended formulation route for tablets, injections, capsules, powders, granules, premix, or solutions.

The active fraction is standardised by virus titre expressed as median tissue culture infectious dose (TCID50) per millilitre or per gram. The compendial potency benchmark is derived from 9 CFR 113.103 for feline panleukopenia vaccine and the European Pharmacopoeia monograph 0250. For the live-attenuated model, post-reconstitution titre is not less than 10^7.0 TCID50/mL. The inactivated whole-virus model is standardised by pre-inactivation titre and antigen mass, because infectivity is no longer measurable after beta-propiolactone treatment. The product is differentiated from final adjuvanted vaccines by the absence of added adjuvant, by the absence of a final dosage-form diluent, and by retained flexibility for the receiving manufacturer to select preservative-free or preserved, oral or parenteral, immediate-release or enteric-coated matrices. This flexibility imposes a strict cold-chain and low-shear processing burden not present with small-molecule chemical APIs.

The inclusion of tablets, capsules, powders, granules, premix, and solutions in the target formulation list reflects the API’s lyophilised or spray-dried physical format, not a demonstrated stability of live parvovirus in every oral matrix. For solid oral dosage forms, the live-attenuated fraction should only be processed by freeze-drying, spray-drying with outlet air temperature below 45°C, or low-temperature granulation. Infectivity loss in aqueous granulation above 40°C and under high-shear wet massing is the principal manufacturing failure mode observed in pilot campaigns. These constraints are specified in the formulation section below.

What Release Specifications Are Applied to the Purified Virus Fraction Before Formulation?

For each batch of the API, release is conditional on identity, purity, potency, and safety tests that follow biological-product and host-cell requirements rather than a conventional chemical pharmacopoeial monograph. Sterility is assessed according to USP <71> and Ph. Eur. 2.6.1; mycoplasma absence is demonstrated by Ph. Eur. 2.6.7; bacterial endotoxin is controlled to <0.5 EU/dose for parenteral applications using USP <85> or Ph. Eur. 2.6.14. Identity is fixed by parvovirus-specific polymerase chain reaction amplification and sequencing of the capsid protein gene; live-virus immunofluorescence with an FPV-specific monoclonal antibody is required to confirm the antigenic phenotype. Virus titre is determined on CRFK cells in microtitration plates and calculated by the Spearman-Kärber method. The release limit for the live-attenuated lyophilised API is ≥10^7.0 TCID50/mL after reconstitution in sterile water for injection. The inactivated whole-virus model is released only after three blind passages show no cytopathic effect, confirming inactivation with beta-propiolactone.

Residual moisture in lyophilised powder is controlled to ≤3.0% w/w by Ph. Eur. 2.5.12 because higher moisture accelerates hydrolysis of the viral capsid during storage at 2–8°C. Host-cell protein and residual bovine serum albumin are monitored by enzyme-linked immunosorbent assay; the acceptance limit is manufacturer-registered and is typically below 50 ng/dose for parenteral presentations, but no harmonised compendial limit exists. Residual beta-propiolactone in the inactivated model is controlled to <5 ppm by gas chromatography; the exact limit varies with national registration. Production-scale lyophilisation records commonly show a 0.2–0.5 log10 TCID50 loss during drying, requiring the pre-freeze-drying titre to be formulated at 10^7.5–10^8.0 TCID50/mL. This overage is validated compensation for the drying phase and is confirmed by three consecutive qualification batches. The liquid inactivated model is less sensitive to freeze-drying loss but is not compatible with repeated freeze-thaw cycles; more than two freeze-thaw cycles can produce visible aggregate and reduce antigen recovery by filtration.

Adventitious virus testing follows 9 CFR 113.53 or Ph. Eur. 2.6.16 using indicator cells and polymerase chain reaction for feline retroviruses. The freeze-dried live API must be reconstituted with water at 20–25°C and used within 2 h unless a proprietary stabiliser has been validated for longer holding. Long-term storage of the lyophilised live API is at −20°C±5°C; at 2–8°C it is typically stable for 12 months when residual moisture is controlled and the container closure is intact. Frozen liquid live harvest is stored at ≤−60°C to preserve titre before lyophilisation.

When Lyophilised Live Virus Enters Solid-Dosage Mixing, Granulation, or Compression

Because the live-attenuated fraction is a thermolabile biological particle and feline parvovirus virions are roughly 18–26 nm non-enveloped icosahedra, their small size allows filtration through sterilising-grade membranes but also makes them susceptible to liquid-air interfacial stress and surface adsorption on hydrophobic tablet punch faces. In tablet manufacture, direct compression is not recommended unless the API is first lyophilised with mannitol or dextran lyoprotectants and compressed at controlled relative humidity. Published data for this specific configuration are limited; feasibility must be verified by virus titration after each compaction stage.

For granules and dry powders, low-temperature fluid-bed granulation with inlet air ≤45°C and product temperature ≤30°C is preferred. Wet granulation using aqueous binder above 40°C or an organic solvent concentration greater than 10% v/v has been associated with measurable titre loss in development lots, but the precise failure threshold varies with stabiliser composition and residual moisture. The granulation binder should be prepared with trehalose or gelatin hydrolysate in phosphate buffer pH 7.2–7.6. After drying, the granules should be sieved gently; oscillating granulators reduce fines but can generate shear. Total aerobic count and moisture are rechecked after any 24 h open handling period, because condensation in feed premixes and unsealed granulation bowls is a recurring source of local water-activity increase.

For hard capsules, filling lyophilised powder or spray-dried multiparticulates is preferred over direct compression because capsule filling avoids the high compression force that can mechanically disrupt the capsid. Capsule filling should be conducted at ≤25°C and 30–35% RH; residual moisture in the capsule shell can transfer into the API and raise water activity, which is a stability-limiting variable for live virus. Enteric-coated multiparticulates are the only oral solid presentation with a plausible pH-protection rationale, because unprotected live virus exposed to gastric pH below 3.0 is likely to undergo capsid conformational change and should not be assumed to retain infectivity. A dissolution or disintegration test alone is not informative for a live viral API; virus titre after residence in simulated gastric fluid at 37°C for 30 min must be included in the design of experiments.

For injectable finished products, the API is reconstituted or diluted in sterile phosphate buffer pH 7.2–7.6 containing 1–2% w/v trehalose and 0.5–1% w/v gelatin hydrolysate. The solution should be filtered through a 0.22 µm membrane only when the titre is sufficient to accept an adsorptive loss of up to 0.5 log10 TCID50; low-protein-binding polyvinylidene fluoride membranes are preferred. Preservatives are not added to live vaccine solutions unless compatibility is demonstrated. Thiomersal and quaternary ammonium preservatives are generally considered incompatible with live parvovirus, and a matrix preservation study is required before any preserved solution can be registered.

For oral solutions and feed premixes, the lyophilised powder is blended with lactose or dextrose carrier in a low-shear tumbler blender. Ribbon blenders and high-shear mixers generate heat and mechanical stress that can reduce infectivity and increase segregation of the low-bulk-density lyophile. Homogeneity must be re-demonstrated after transfer, and the total aerobic plate count of the premix is rechecked because the carrier may have a higher bioburden than the sterile API. These operations are not normal small-molecule blending steps and require a negative-pressure or laminar-flow zone to protect operators and to prevent cross-contamination with chemical products.

Compared with conventional chemical APIs and many recombinant subunit vaccines, this veterinary-grade FPV API is defined by a biological release mechanism rather than a chemical purity specification. The live-attenuated model differs from inactivated whole-virus and recombinant VP2 products in three measurable ways: initiation of immunity, safety in susceptible populations, and processing robustness. In young cats, live FPV vaccines can induce a protective response after a single dose because the attenuated virus replicates in the intestinal and lymphoid tissues; inactivated vaccines usually require two doses and an adjuvant to reach a comparable response. However, live attenuated FPV is contraindicated in pregnant queens and in animals with severe immunosuppression, and it cannot be sterilised by heat or terminal gamma irradiation without total loss of infectivity. Published data on gamma irradiation of live feline parvovirus are limited; the standard release is therefore aseptic filtration plus aseptic lyophilisation. Recombinant VP2 subunit API avoids replication risk and can be more resistant to mild thermal stress, but published data for its oral or solid-dosage stability in feline formulations are limited. The inactivated whole-virus API is preferred for tablets and premixes only when high antigen mass and enteric protection are achieved; without an adjuvant it is less immunogenic by the oral route and may require substantial potency overage.

An additional difference from chemical antiviral small molecules is that the FPV vaccine API is not a single molecule with a fixed molecular weight; it is a structured virus particle whose capsid is composed of VP1 and VP2 proteins and encloses a single-stranded DNA genome of approximately 5.1–5.3 kb depending on the strain. This biological complexity means that chromatographic purity methods such as HPLC-UV are insufficient for potency. Potency is expressed in infectivity units or antigen mass units, and batch release is governed by biological variability across cell banks, not by a narrow chemical process capability index. The API must therefore be used by a qualified manufacturer with established cold-chain control, mycoplasma and extraneous-agent testing capacity, and a validated biological containment programme. It is not a direct-administration product; it is a starting material for licensed veterinary biological products.

Stability of the live virus in a specific final matrix cannot be assumed from freeze-dried bulk stability alone; a matrix-specific holding-time study is required, because excipients such as magnesium stearate, sodium starch glycolate, and high-surface-area silicas can adsorb or inactivate the virion during compaction and storage. Lot-to-lot variation in the cell substrate and in the lyophilisation heat-transfer profile is controlled by using qualified working cell banks and by validating the chamber load for each vial or tray configuration.